Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients
NCT02575066 · The Netherlands Cancer Institute · PHASE2 · terminated · last registry update 2019-06-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “stopping rule” | – | Registry record, The Netherlands Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-17Results posted on the registry: Northwestern University, temozolomide + pazopanib hydrochloride (NCT01465659)
- 2020-06-17Results posted on the registry: Boehringer Ingelheim, BIBF 1120 + sunitinib (NCT01024920)
- 2020-06-16Results posted on the registry: Hope Rugo, MD, Pazopanib (NCT01466972)
- 2020-06-09Results posted on the registry: Washington University School of Medicine, Pazopanib (NCT02300545)
- 2020-06-01Results posted on the registry: National Cancer Institute (NCI), Pazopanib Hydrochloride (NCT01841736)
- 2020-06-01Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Famitinib capsules + Sunitinib Capsules (NCT04409223)
- 2020-05-28Results posted on the registry: Daiichi Sankyo, PLX3397 + vemurafenib (NCT01826448)
- 2020-05-28Also stopped (terminated): Daiichi Sankyo, PLX3397 + vemurafenib (NCT01826448)
- 2020-05-20Phase 3 first posted: Shanghai Junshi Bioscience Co., Ltd., Biological : Toripalimab Drug: Axitinib + sunitinib (NCT04394975)
- 2020-05-14Results posted on the registry: Hope Rugo, MD, PLX3397 + Eribulin (NCT01596751)
- 2020-05-12Results posted on the registry: Tracon Pharmaceuticals Inc., TRC105 and Pazopanib (NCT01975519)
- 2020-05-12Results posted on the registry: Tracon Pharmaceuticals Inc., TRC105 + Votrient (NCT02979899)
- 2020-04-24Results posted on the registry: Daiichi Sankyo Co., Ltd., Pexidartinib (NCT02734433)
- 2020-04-24Results posted on the registry: Daiichi Sankyo, AC220 (NCT00462761)
- 2020-04-22Results posted on the registry: Daiichi Sankyo, Treatment A - 400 mg Fasting + Treatment B - 400 mg Fed (NCT03901313)
- 2020-04-13Also stopped (withdrawn): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nivolumab + Cabrilizumab (NCT03768531)
- 2020-04-09Results posted on the registry: Daiichi Sankyo Co., Ltd., PLX3397 (NCT02975700)
- 2020-04-08Results posted on the registry: Mayo Clinic, Pazopanib Hydrochloride (NCT01767636)
- 2020-04-06Results posted on the registry: Daiichi Sankyo, PLX3397 (NCT01004861)
- 2020-04-06Results posted on the registry: Medical University of South Carolina, Gemcitabine and Pazopanib + Gemcitabine and Docetaxel (NCT01593748)
- 2020-03-19Results posted on the registry: Daiichi Sankyo, Tolbutamide + Midazolam (NCT03291288)
- 2020-03-05Also stopped (terminated): Daiichi Sankyo, PLX3397 + Pembrolizumab (NCT02452424)
- 2020-03-04Also stopped (terminated): Daiichi Sankyo, PLX3397 (NCT01499043)
- 2020-03-03Results posted on the registry: National Cancer Institute (NCI), Pazopanib + Pazopanib Hydrochloride (NCT02601209)
- 2020-03-03Also stopped (terminated): Daiichi Sankyo, PLX3397 (NCT01349036)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision